共 234 条
[1]
Rapezzi C(2015)Cardiac amyloidosis: the great pretender Heart Fail Rev 20 117-124
[2]
Lorenzini M(2012)Cardiac transthyretin amyloidosis Heart. 98 1546-1554
[3]
Longhi S(2019)Clinical presentation, diagnosis and treatment of TTR amyloidosis J Neuromuscul Dis 6 189-199
[4]
Milandri A(2018)Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis N Engl J Med 379 11-21
[5]
Gagliardi C(2013)THAOS - The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis Curr Med Res Opin 29 63-76
[6]
Bartolomei I(2019)Tafamidis for autonomic neuropathy in hereditary transthyretin (ATTR) amyloidosis: a review Clin Auton Res 29 19-24
[7]
Salvi F(2019)Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis Circulation. 140 16-26
[8]
Maurer MS(2018)Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy N Engl J Med 379 1007-1016
[9]
Dungu JN(2018)Inotersen treatment for patients with hereditary transthyretin amyloidosis N Engl J Med 379 22-31
[10]
Anderson LJ(2018)A new staging system for cardiac transthyretin amyloidosis Eur Heart J 39 2799-2806